Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE versus SERENTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE versus SERENTIL.
LOXITANE vs SERENTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine is a typical antipsychotic that exerts its effects primarily by blocking dopamine D2 receptors in the mesolimbic pathway. It also has affinity for serotonin 5-HT2A, histamine H1, alpha1-adrenergic, and muscarinic receptors.
SERENTIL (mesoridazine) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminic effects. It has high affinity for D2, 5-HT2A, and alpha-1 receptors.
Oral: Initial 10 mg twice daily; may increase up to 250 mg/day in divided doses. IM: 12.5-50 mg every 4-6 hours.
Oral: 50–100 mg 3 times daily; maximum 400 mg/day. IM: 25 mg every 4–6 hours.
None Documented
None Documented
12-18 hours (terminal). Steady state achieved within 3-5 days; dosing adjustments for renal/hepatic impairment.
Terminal elimination half-life is approximately 24-30 hours in adults. Does not correlate well with duration of antipsychotic effect due to active metabolite formation.
Renal excretion accounts for 50-60% (primarily as metabolites, <1% unchanged). Fecal/biliary elimination accounts for 25-35% (via bile).
Primarily renal (70-80% as conjugated and unconjugated metabolites) and fecal (15-20%). Biliary excretion contributes to enterohepatic circulation.
Category C
Category C
Antipsychotic
Antipsychotic